The pharmaceutical industry has systematically corrupted medical science through a process that mirrors the tobacco industry's manipulation of research on smoking. Understanding this process is prerequisite to evaluating any drug claim.
The Tobacco Science Template
"It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines."
"Marcia Angell, MD"
The tobacco industry's response to evidence linking smoking to cancer established the template for industry manipulation of science:
- Fund counter-research to create the appearance of scientific controversy
- Attack the credibility of scientists whose findings threaten profits
- Promote alternative explanations that shift blame
- Capture regulatory agencies through revolving-door employment
- Fund medical education to bias physicians
The pharmaceutical industry has used every one of these tactics, at a scale that dwarfs the tobacco industry.
How Pharma Corrupts Research
Selective publication: Companies register trials but publish only those with positive results. A 2008 analysis of 74 FDA-registered antidepressant trials found that 37 of 38 positive trials were published, but only 14 of 36 negative trials were published. The published literature showed 94% of trials positive; the actual data showed 51%.
Outcome switching: Companies pre-register trials with one primary outcome, then switch to a different outcome after seeing the data — choosing whichever outcome looks best.
Ghost writing: Companies write papers and pay academic physicians to put their names on them. A 2009 analysis found that 11% of articles in major medical journals were ghost-written.
A 2008 analysis of antidepressant trials found that the published literature showed 94% positive results. The actual FDA data showed 51% positive. The difference is publication bias.
Surrogate endpoints: Companies test drugs on surrogate endpoints (e.g., cholesterol levels, bone density) rather than clinical outcomes (e.g., heart attacks, fractures). Drugs that improve surrogate endpoints often do not improve clinical outcomes.
Industry-funded trials: Industry-funded trials are 4 times more likely to show positive results than independently funded trials, even after controlling for study quality.
The Key Opinion Leader System
Pharmaceutical companies identify influential physicians — key opinion leaders (KOLs) — and pay them to speak at conferences, write review articles, and consult for the company. KOLs are paid to promote company products and to create the impression of independent expert endorsement.
The Regulatory Capture Problem
The FDA approves drugs based primarily on industry-funded trials. The FDA's drug approval division is funded by user fees paid by the pharmaceutical industry — creating a structural conflict of interest. Former FDA officials routinely take jobs in the pharmaceutical industry.
What This Means for Patients
Every drug claim must be evaluated with the knowledge that the supporting evidence has likely been systematically distorted. The published literature systematically overstates drug benefits and understates drug risks. Independent evaluation of the raw trial data — which companies routinely refuse to share — is essential.